Aggarwal Sumit 4

What Happened
Sumit Aggarwal, a reported 10% owner of Eloxx Pharmaceuticals (ELOX), executed multiple equity transactions spanning 2022–2026. Notable items include option/derivative exercises (e.g., 260,946 shares exercised on 2026-02-28 at $0.15 for $39,142 and 196,880 shares on 2025-08-14 showing nominal consideration of $20) and large awards/grants (a 1,000,000-share grant on 2025-09-19 and a 3,597,090-share derivative award the same date). Several earlier RSU grants and option conversions are reported, and multiple dispositions to the issuer (likely tax withholding or surrender of shares on vesting/exercise) are also listed.

Key Details

• Filing date: May 8, 2026; Reported period includes transactions dating back to Feb 6, 2022 — the filing appears to consolidate multiple earlier transactions (i.e., late filing of historical activity).
• Major transactions called out in the filing:
  • 2026-02-28: exercised 260,946 shares at $0.15; total reported cash paid ~$39,142.
  • 2025-08-14: exercised/conversion of 196,880 shares reported with nominal consideration of $20.
  • 2025-09-19: received grants/awards totaling 1,000,000 shares and 3,597,090 derivative shares (reported as acquired at $0).
  • Multiple RSU grants and option exercises/dispositions between 2022–2025, including dispositions to issuer on 2024-10-16 (likely tax withholding).
• Shares owned after these transactions: not specified in the excerpt provided.
• Footnotes of note:
  • F1/F2: Some RSUs were granted and fully vested on grant; each RSU converts to one share.
  • F3/F11/F12/F13: Several options/awards had multi-year vesting schedules; the Board accelerated vesting on some exercised options.
  • F5/F7/F8/F10: Some earlier options were cancelled and replaced with new options having lower exercise prices.
• No indication of a 10b5-1 plan or other trading plan in the provided notes.

Context
These filings include both awards/grants (A) and option/derivative exercises (M). Awards and RSUs are acquisitions (a bullish signal in that the insider received shares), while exercises are conversions of existing derivative instruments into common stock; several exercises show immediate dispositions to the issuer which commonly reflect tax withholding or cashless exercise mechanics rather than open‑market sales. As a 10% owner, Aggarwal's transactions are material by regulation but do not by themselves indicate the insider's view of the company — they document compensation/vesting and option activity. The consolidated/late nature of the filing (filed 2026-05-08 covering earlier years) is relevant for timing and investor interpretation.